Related Experiment Videos
New approaches to transplant immunosuppression
B D Kahan1, R A Kirken, S M Stepkowski
1Division of Immunology and Organ Transplantation, University of Texas Medical School-Houston, Houston, Texas 77024, USA
Transplantation Proceedings
|September 10, 2003
Summary
Developing novel immunosuppressants requires targeting pathways specific to the adaptive immune response. This study explores new strategies to identify and develop these targeted immunosuppressive drugs, minimizing collateral toxicities.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- Current immunosuppressive drugs target widely distributed molecules, leading to significant toxicities.
- Identifying targets specific to the adaptive immune response is crucial for developing safer immunosuppressants.
Purpose of the Study:
- To explore strategies for identifying and developing novel immunosuppressants with improved specificity.
- To overcome the collateral toxicities associated with current immunosuppressive therapies.
Main Methods:
- Utilized molecular design based on ligand-antagonist structural similarity.
- Employed complementary DNA oligonucleotides to inhibit target messenger RNA.
- Conducted functional comparisons using inhibitory profiles of candidate compounds.
Main Results:
- Identified antagonists for selectins, intercellular adhesion molecule-1, and Janus kinase 3.
- These lead compounds demonstrated potential in modulating alloimmune responses and ischemia-reperfusion injuries.
Conclusions:
- New strategies can identify specific targets within the adaptive immune response for immunosuppression.
- Targeted immunosuppressants hold promise for reducing off-target toxicities and improving therapeutic outcomes.